Back to top

Image: Bigstock

Top Ranked Value Stocks to Buy for March 22nd

Read MoreHide Full Article

Here are four stocks with buy rank and strong value characteristics for investors to consider today, March 22nd:

DXC Technology Company (DXC - Free Report) : This information technology services and solutions provider has a Zacks Rank #2 (Buy), and seen the Zacks Consensus Estimate for its current year earnings rising 1% over the last 60 days.

DXC Technology has a price-to-earnings ratio (P/E) of 7.94, compared with 23.00 for the industry. The company possesses a Value Score of A.

BT Group plc (BT - Free Report) : This communications services provider has a Zacks Rank #2, and seen the Zacks Consensus Estimate for its current year earnings rising 3% over the last 60 days.

BT has a price-to-earnings ratio (P/E) of 8.86, compared with 14.00 for the industry. The company possesses a Value Score of A.

BT Group PLC PE Ratio (TTM)

BT Group PLC PE Ratio (TTM)

BT Group PLC pe-ratio-ttm | BT Group PLC Quote

Blue Capital Reinsurance Holdings Ltd. (BCRH - Free Report) : This collateralized reinsurance provider in the property catastrophe market has a Zacks Rank #2, and seen the Zacks Consensus Estimate for its current year earnings rising 7.4% over the last 60 days.

Blue Capital Reinsurance has a price-to-earnings ratio (P/E) of 8.99, compared with 23.40 for the industry. The company possesses a Value Score of B.

PPDAI Group Inc. (PPDF - Free Report) : This investment holding company has a Zacks Rank #2, and seen the Zacks Consensus Estimate for its current year earnings rising 2.1% over the last 60 days.

PPDAI has a price-to-earnings ratio (P/E) of 4.42, compared with 5.20 for the industry. The company possesses a Value Score of A.

See the full list of top ranked stocks here

Learn more about the Value score and how it is calculated here.

Breakout Biotech Stocks with Triple-Digit Profit Potential

The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.

Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.

See these 7 breakthrough stocks now>>



More from Zacks Zacks #1 Rank Additions

You May Like

Published in